CEACAM1/CD66a Antibody (Immunomedics patent anti-CEACAM5) [DyLight 650]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28440C
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 650 (Excitation = 652 nm, Emission = 672 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Immunomedics patent anti-CEACAM5
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary
Immunogen
CEACAM5 / CEA / CD66e
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CEACAM-1/CD66a
Long Name
Carcinoembryonic Antigen-related Cell Adhesion Molecule 1
Alternate Names
BGP1, Biliary Glycoprotein 1, CD66a, Cea-1, CEACAM1, Hv-1, Hv-2, MHVR
Gene Symbol
CEACAM1
Additional CEACAM-1/CD66a Products
Product Specific Notices
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...